NCT07741825 · University of Texas at Austin
Mindfulness-based Relapse Prevention for Peer Workers
(MBRP)
What this study is about
Adapt and test the effectiveness of MBRP for substance use peer workers compared to a the usual treatment (referral to 12-step) control condition on substance use, relapse risk, and burnout among peers in a pilot hybrid type 1 trial.
View original scientific description
Adapt and test the effectiveness of MBRP for substance use peer workers compared to a standard of care (referral to 12-step) control condition on substance use, relapse risk, and burnout among peers in a pilot hybrid type 1 trial. The goal of this clinical trial is to learn if Mindfulness-Based Relapse Prevention can reduce substance use, relapse risk, and burnout among substance use peer workers. The objectives are to: 1. Identify the causes, consequences, and risk and protective factors for relapse among peer workers; 2. Identify peers' preferences related to MBRP content, structure, and delivery; 3. Adapt the MBRP intervention for peer workers; and 4. Assess the preliminary effectiveness and implementation outcomes of the adapted MBRP intervention. Researchers will compare MBRP to referral to 12-step (standard of care) to see if MRBP works to reduce substance use, relapse risk, and burnout.
Interventions
BEHAVIORAL
Mindfulness Based Relapse Prevention
MBRP for peer workers consists of 8 weekly 2-hour virtual sessions.
BEHAVIORAL
Standard of Care
Referral to 12-step programming
Primary outcome measures
Change from baseline in biologically verified substance use at 1, 3, and 6 months as measured by Saliva Drug Assays
Time frame: From enrollment to 6 months
Saliva drug assays detecting the presence or absence of commonly used substances. Results are reported as positive or negative for each substance tested, with negative results indicating a better outcome.
Change from baseline in self-reported substance use days at 1, 3, and 6 months as measured by the Timeline Follow-Back (TLFB)
Time frame: From enrollment to 6 months
A calendar-based interview assessing daily substance use over a specified recall period. Outcomes are reported as the number of days of substance use during the assessment period, with fewer days indicating a better outcome.
Change from baseline in relapse warning Signs at 1, 3, and 6 months as measured by the Advance Warning of Relapse (AWARE) Questionnaire
Time frame: From enrollment to 6 months
A 28-item; 7-point Likert-type scale assessing warning signs associated with relapse risk. Total scores range from 28 to 196, with higher scores indicating greater relapse risk (worse outcome).
Change from baseline in professional quality of life at 1, 3, and 6 months as measured by the Professional Quality of Life Scale (ProQOL)
Time frame: From enrollment to 6 months
A 30-item; 5-point Likert-type scale assessing professional quality of life across three 10-item subscales: Compassion Satisfaction, Burnout, and Secondary Traumatic Stress. Each subscale score ranges from 10 to 50. Higher Compassion Satisfaction scores indicate a better outcome, whereas higher Burnout and Secondary Traumatic Stress scores indicate worse outcomes.
Post-intervention perceived feasibility of the intervention as measured by the Feasibility of Intervention Measure (FIM)
Time frame: Immediately after the final intervention session
A 4-item; 5-point Likert-type scale assessing the perceived feasibility of an intervention. Total scores range from 4 to 20, with higher scores indicating greater perceived feasibility (better outcome).
Post-intervention perceived acceptability of the intervention as measured by the Acceptability of Intervention Measure (AIM)
Time frame: Immediately after the final intervention session
A 4-item; 5-point Likert-type scale assessing the perceived acceptability of an intervention. Total scores range from 4 to 20, with higher scores indicating greater perceived acceptability (better outcome).
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Are \> 18 years old
- Fluent in English
- Be currently employed in a substance use peer support role
- At-risk for SUD relapse as measured by a craving score of \>15 on the adapted Penn Alcohol Craving Scale
Exclusion criteria
- Have a cognitive impairment that jeopardizes informed consent
- Actively suicidal or psychotic
Where
- Austin, Texas
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Aug 7, 2026 · Source of record for eligibility and locations